Young-Ho Lee
Vorstandsvorsitzender bei Immunique Co. Ltd.
Aktive Positionen von Young-Ho Lee
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Hanyang University | Corporate Officer/Principal | - | - |
Immunique Co. Ltd.
 Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Young-Ho Lee
Ehemalige bekannte Positionen von Young-Ho Lee
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NANOENTEK, INC. | Direktor/Vorstandsmitglied | 24.03.2022 | 08.09.2023 |
| Independent Dir/Board Member | 24.03.2022 | 08.09.2023 |
Ausbildung von Young-Ho Lee
| Hanyang University | Doctorate Degree |
Statistik
International
| Südkorea | 4 |
Operativ
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NANOENTEK, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
- Börse
- Insiders
- Young-Ho Lee
- Erfahrung
